MOTS-c for Longevity and Anti-Aging: Protocol, Dosing, and What to Expect

What this protocol is for

MOTS-c is one of the most mechanistically interesting peptides in the longevity space. The molecule is a mitochondrial-derived peptide encoded by the mitochondrial genome itself rather than the nuclear genome, which makes it biologically distinct from the rest of the peptide catalogue. Mechanism: MOTS-c activates AMPK (the master metabolic switch), supports mitochondrial function across tissues, improves insulin sensitivity, and modulates the metabolic flexibility that underlies healthy aging.

The clinical pattern in user reports is consistent with the mechanism. Improvements in metabolic markers (insulin sensitivity, fasting glucose, fasting insulin) over 8 to 12 weeks. Better exercise capacity and recovery between sessions. Subjective energy improvements that align with mitochondrial function support. Anecdotally, users running MOTS-c for longevity report functional gains that feel like the metabolic side of getting younger: more efficient energy use, better fasted-state tolerance, faster training recovery, easier body composition management.

Used by many in the recovery / biohacking space as one of the more evidence-supported longevity peptides. Research shows AMPK activation is one of the load-bearing mechanisms behind caloric-restriction longevity effects, and MOTS-c hits that lever pharmacologically. Run this as a tactical, legal performance layer for metabolic-longevity work. Pair with NAD+ support and other mitochondrial protocols for a comprehensive metabolic-aging stack.

Dose for longevity and anti-aging

5 to 10 mg subcutaneous, 1 to 3 times per week. Common rhythm: 10 mg once weekly or 5 mg twice weekly. Higher-frequency dosing (3 times per week) is used for more intensive metabolic protocols; weekly dosing is sufficient for maintenance longevity work. Abdominal subcutaneous is the standard route.

Cycle length

8 to 12 weeks per cycle, 4 to 6 weeks off, 2 to 3 cycles per year. The metabolic effects build cumulatively across cycles; long-term effects on metabolic-aging markers come from repeated cycling over years rather than single-cycle changes.

Stack pairings

Commonly stacked with NAD+ (oral supplement).

Expected timeline

Week 2–4: subjective energy improvements, better fasted-state tolerance, faster recovery between training sessions. Week 4–8: metabolic markers (insulin sensitivity, fasting glucose) typically shift in bloodwork. Week 8–12: cumulative effects on body composition and exercise capacity become visible. Long-term metabolic-aging effects build across repeated cycles over years.

Common mistakes

• Running MOTS-c as a standalone longevity protocol. The peptide addresses metabolic-aging biology; cardiovascular, cognitive, and immune-aging are separate layers requiring separate work.
• Skipping bloodwork. MOTS-c shifts metabolic markers and verification matters. Pre-cycle fasting glucose, fasting insulin, HOMA-IR, and (where possible) HbA1c give the baseline. Post-cycle bloodwork shows whether the protocol is doing what the mechanism predicts.
• Treating MOTS-c as a fat-loss drug rather than a metabolic-flexibility tool. The body composition effects come from improved insulin sensitivity and mitochondrial function, not from direct lipolysis or appetite suppression.
• Expecting GLP-1-tier metabolic effects. MOTS-c is a slow-build mitochondrial protocol; the metabolic improvements are real but modest in any single cycle. The longevity case is built on cumulative effect across years.